Sunshine Biopharma, Inc. (SBFM)

NASDAQ: SBFM · IEX Real-Time Price · USD
0.0605
+0.0035 (6.14%)
At close: Mar 28, 2024, 4:00 PM
0.0844
+0.0239 (39.50%)
After-hours: Mar 28, 2024, 7:59 PM EDT
6.14%
Market Cap 6.02M
Revenue (ttm) 20.35M
Net Income (ttm) -26.77M
Shares Out 99.45M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,258,777
Open 0.0571
Previous Close 0.0570
Day's Range 0.0570 - 0.0630
52-Week Range 0.0440 - 1.4000
Beta -1.09
Analysts Strong Buy
Price Target 2.60 (+4,197.52%)
Earnings Date May 8, 2024

About SBFM

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; ... [Read more]

Sector Healthcare
Founded 2006
Employees 46
Stock Exchange NASDAQ
Ticker Symbol SBFM
Full Company Profile

Financial Performance

In 2022, SBFM's revenue was $4.35 million, an increase of 1802.41% compared to the previous year's $228,426. Losses were -$26.74 million, 115.0% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SBFM stock is "Strong Buy" and the 12-month stock price forecast is $2.6.

Price Target
$2.6
(4,197.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeu...

6 weeks ago - Accesswire

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeu...

6 weeks ago - Accesswire

Sunshine Biopharma Moves Principal Office to New York City

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeut...

4 months ago - GlobeNewsWire

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

MONTREAL, QC / ACCESSWIRE / November 13, 2023 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeut...

4 months ago - Accesswire

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

No Immediate Effect on Nasdaq Listing or Trading of the Company's Common Stock MONTREAL, QC / ACCESSWIRE / September 21, 2023 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical ...

6 months ago - Accesswire

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeuti...

8 months ago - GlobeNewsWire

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

NEW YORK, NY / ACCESSWIRE / May 16, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM). A...

11 months ago - Accesswire

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including...

11 months ago - GlobeNewsWire

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including...

11 months ago - GlobeNewsWire

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including...

11 months ago - GlobeNewsWire

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas includi...

1 year ago - GlobeNewsWire

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas includin...

1 year ago - GlobeNewsWire

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas includin...

1 year ago - GlobeNewsWire

Sunshine Biopharma Announces Share Repurchase Program

MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas includin...

1 year ago - GlobeNewsWire

Sunshine Biopharma's Annual Letter to Shareholders

MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas includin...

1 year ago - GlobeNewsWire

4 Stocks Meeting GuruFocus' Value Screens in December

As investors prepare for the holiday season, GuruFocus' value screeners identified several stocks that meet screening criteria based on key principles taught by Benjamin Graham, Peter Lynch and Berksh...

Other symbols: RMCACCWFG
1 year ago - GuruFocus

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, includi...

1 year ago - GlobeNewsWire

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drug...

1 year ago - GlobeNewsWire

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings

1 year ago - GlobeNewsWire

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development an...

1 year ago - GlobeNewsWire

Sunshine Biopharma: An Opportunity Knocking?

Investors with a very high appetite for risk and seeking ultra-high-growth stocks can find potential opportunities within the pharma and biotech domain. Investing in development-stage biopharma compan...

2 years ago - GuruFocus

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, developmen...

2 years ago - GlobeNewsWire

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

NEW YORK, NY / ACCESSWIRE / April 28, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ:SBFM) ...

2 years ago - Accesswire

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

MONTREAL, April 26, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, developmen...

2 years ago - GlobeNewsWire

Why Sunshine Biopharma Stock Is Surging

Sunshine Biopharma Inc (NASDAQ: SBFM) shares are trading higher Monday after the company announced it filed a United States provisional patent application covering the recently communicated mRNA molec...

2 years ago - Benzinga